Early tumor and leukemia response to alkyllysophospholipids in a phase I study.
In a phase I study on the toxicity and toleration of alkyllysophospholipids, tumor and leukemia responses have been noted in the first treated patients. Six patients with solid malignomas of different histologic types and one patient with acute myeloid leukemia are evaluable so far. All of them suffered from metastatic or wide-spread disease, were refractory to adequate polychemotherapy or other treatment modalities, or have been found untreatable because of poor general condition. Four cases revealed objective tumor and leukemia response with a minor response in a hypernephroma, two partial remissions in nonsmall cell bronchogenic carcinomas and reduction of leukemic blasts to less than 10% in acute myeloid leukemia. Limiting toxicity started with doses of 20 mg/kg given daily showing transient injury of renal and liver functions.
D000293:Adolescent; D000368:Aged; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007938:Leukemia / Q000188:drug therapy*; D008099:Liver / Q000187:drug effects; D008175:Lung Neoplasms / Q000188:drug therapy*; D008244:Lysophosphatidylcholines / Q000009:adverse effects / Q000627:therapeutic use; D008246:Lysophospholipids; D008297:Male; D008875:Middle Aged; D010743:Phospholipids / Q000009:adverse effects / Q000627:therapeutic use*
D008244:Lysophosphatidylcholines; D008246:Lysophospholipids; D010743:Phospholipids; C026564:stearoyl alpha-lysolecithin